Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study. - Wikidata - awgldk - TriplyDB

Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study.

Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study.

http://www.wikidata.org/entity/Q33918044

about

Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer Targeting FGFR in Squamous Cell Carcinoma of the Lung.Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer.Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.

P2860

Q33356339-514508EA-5611-4D28-9D75-3B1BA2CDFBF5 Q33417869-0EFA0AD5-0425-4FA1-AEE7-132917DEA046 Q35659433-301CF526-65C4-46C9-881E-7BECBD2F5BAD Q36671812-1E49B45C-0B69-49EC-A60C-955B50CCFD50 Q38690050-167A4104-81BF-456C-B75F-F1271D03A886 Q39036230-5A8FA654-22B3-42B7-9B5C-D83BE4956AEF Q43515124-5A885BFC-35A9-41FB-92B2-3AA46F61C340 Q48352556-DBCC7669-6206-414B-AA56-C5CB20FC3016 Q50885562-A8E095F7-C8D9-425B-886D-F2E3B02DDA8D

P2860

Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study.

http://www.wikidata.org/entity/Q33918044

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Cediranib in combination with ...... a phase I multi-cohort study.

@ast

Cediranib in combination with ...... a phase I multi-cohort study.

@en

type

label

Cediranib in combination with ...... a phase I multi-cohort study.

@ast

Cediranib in combination with ...... a phase I multi-cohort study.

@en

prefLabel

Cediranib in combination with ...... a phase I multi-cohort study.

@ast

Cediranib in combination with ...... a phase I multi-cohort study.

@en

P1433

Q33918044-761D3CE3-4295-4C4D-8D43-67791B829349

P1476

Q33918044-18E39259-5DBE-4575-9705-8E2C706FA8AD

P2093

Q33918044-053714FA-D1CD-4BBA-A8F1-997F2E8A31DD

Q33918044-1B652E6A-B71B-4C92-AEE1-884F9F35005A

Q33918044-41DBB592-88DE-49BA-883F-16C87B1958A0

Q33918044-4E10482F-1A89-4251-B25B-28705C04BB27

Q33918044-81A73CA9-16BB-481F-9BDF-9B1F5CE0B077

Q33918044-8439B0AC-1190-4066-A158-36C9AC013E5D

Q33918044-A54226CB-5158-425D-AC7A-282A6AAE71F0

Q33918044-BE198264-B006-4AA4-9E88-6D0455F497D0

P2860

Q33918044-0A84E4B6-AF64-4611-9AF7-DEA2E5D30967

Q33918044-0AB2489A-60F7-4D7A-AE5E-31D14D5439E4

Q33918044-1692304D-97B0-4D42-AA5C-C7CEC918EC42

Q33918044-1820388D-196D-442F-A90E-D385800D5D98

Q33918044-1F45EA0F-F8A3-4865-ACAC-6E41A395E5BF

Q33918044-3DA75D88-2AF3-481E-872D-AD7749E20F58

Q33918044-40874E76-FD13-4843-94CD-6064DAA958DA

Q33918044-4D0B9D61-5F71-461F-804F-8F189F9C7987

Q33918044-8F98AE8D-C70B-485A-9D74-E9FBFA21E3B8

Q33918044-921E169B-C791-4889-BEEB-41A768294664

P2888

Q33918044-232C7823-7D01-4783-839B-2C2F58D801C3

P304

Q33918044-7114F6C3-B28D-481E-8042-551FBA42E496

P31

Q33918044-0B918788-56F8-4873-B56F-9029E3E0086E

P356

Q33918044-74EB0439-17AE-4F2F-921E-515010583AD7

P433

Q33918044-95C96007-E193-4038-9422-02AD8D12532B

P478

Q33918044-534F39E4-C8AD-476B-80FC-AFEF30CE98DB

P577

Q33918044-5BAB3F84-8385-4208-94DC-E5F4A7ABC7DA

P6179

Q33918044-DD30018C-5F67-4C5F-85AD-7DDCDF7CEA2B

P698

Q33918044-0CE527C3-F541-4F07-A560-9A48B869C0CC

P932

Q33918044-D9152B4F-AE9A-4C60-86AC-3632FA1C9C1E

P356

S10637-010-9484-5

P1433

Investigational New Drugs

P1476

Cediranib in combination with ...... a phase I multi-cohort study.

@en

P2093

Anthony F Shields

http://www.w3.org/2001/XMLSchema#string

John Xu

http://www.w3.org/2001/XMLSchema#string

Patricia Lorusso

http://www.w3.org/2001/XMLSchema#string

Qi Liu

http://www.w3.org/2001/XMLSchema#string

Shirish Gadgeel

http://www.w3.org/2001/XMLSchema#string

Thomas Puchalski

http://www.w3.org/2001/XMLSchema#string

Tina Guthrie

http://www.w3.org/2001/XMLSchema#string

Ulka Vaishampayan

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the Nati

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

P2888

s10637-010-9484-5

P304

1395-1405

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-010-9484-5

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1001503662

http://www.w3.org/2001/XMLSchema#string

P698

20607586

http://www.w3.org/2001/XMLSchema#string

P932

4102931

http://www.w3.org/2001/XMLSchema#string